Members of the Melanoma Program (MP) examine the basic mechanisms that govern melanoma development, progression, immune escape, and resistance to therapy, and translate laboratory discoveries into novel immunotherapies, molecularly targeted therapies, and combinations for patients with high-risk and advanced melanoma.
Read more about the Melanoma Program
See Program Members
Investigate the mechanisms governing melanoma progression and immune escape to develop improved immunotherapies
Develop more effective therapies and improved biomarkers of clinical outcome for patients with melanoma brain metastases
Translate laboratory findings into novel investigator-initiated clinical trials with correlative studies